Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Salts of aminoquinazoline derivative and application of salts

A diffraction peak and sulfate technology, which can be used in medical preparations containing active ingredients, drug combinations, cardiovascular system diseases, etc., can solve the problems of hindering the binding of EGFR and its inhibitors, increasing the affinity of EGFR and ATP, etc.

Active Publication Date: 2018-06-01
SUNSHINE LAKE PHARM CO LTD
View PDF20 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The T790M mutation is a point mutation in exon 20 of EGFR, and it is one of the more recognized drug resistance mechanisms at present. , leading to changes in the structure of EGFR, hindering the combination of EGFR and its inhibitors or greatly increasing the affinity of EGFR and ATP, so that the ATP affinity is restored to the wild level of EGFR, thus leading to drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salts of aminoquinazoline derivative and application of salts
  • Salts of aminoquinazoline derivative and application of salts
  • Salts of aminoquinazoline derivative and application of salts

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] The succinate crystal form A of the compound shown in embodiment 1 formula (I)

[0130] 1. Preparation of title succinate crystal form A

[0131] The free base (0.259g, 0.501mmol) was added to a mixed solution of methanol (2.0mL) and isopropyl acetate (4.0mL), the temperature was raised to 70°C, and acetic acid of succinic acid (0.142g, 1.20mmol) was added dropwise Isopropyl ester solution (1.0 mL), after dropping, the reaction was naturally cooled to room temperature overnight, filtered with suction, the filter cake was washed with a small amount of isopropyl acetate, and dried under vacuum at room temperature to obtain an off-white solid (0.179 g, 56.26%).

[0132] 2. Identification of the title succinate crystal form A

[0133] (1) Analysis and identification by Empyrean X-ray powder diffraction (XRPD): using Cu-Kα radiation, it has the following characteristic peaks expressed in angle 2θ: 5.52°, 10.70°, 11.11°, 13.24°, 14.51°, 15.44°, 16.04 °,16.54°,17.11°,17....

Embodiment 2

[0135] Embodiment 2 The succinate crystal form B of the compound represented by the formula (I)

[0136] 1. Preparation of title succinate crystal form B

[0137] Add free base (0.516g, 0.998mmol) to ethanol (30.0mL), heat to reflux, filter while hot, continue to reflux the filtrate and add succinic acid (0.248g, 2.10mmol), keep warm for 2.5 hours, and cool the reaction naturally to room temperature, then cooled and crystallized at -15°C, suction filtered, and the filter cake was vacuum-dried at room temperature to obtain a light yellow solid (0.17g, 26.82%).

[0138] 2. Identification of the title succinate crystal form B

[0139] (1) Analysis and identification by Empyrean X-ray powder diffraction (XRPD): using Cu-Kα radiation, it has the following characteristic peaks expressed in angle 2θ: 5.01°, 7.01°, 9.89°, 10.28°, 11.11°, 13.09°, 13.36 °,13.99°,14.52°,15.11°,15.70°,17.07°,18.58°,18.89°,19.16°,20.20°,20.57°,22.80°,23.29°,23.72°,24.40°,24.52°,25.34°, 26.38°,27.07°...

Embodiment 3

[0141] The succinate amorphous of the compound shown in embodiment 3 formula (I)

[0142] 1. Preparation of the title succinate amorphous

[0143] Add the free base (5.17g, 10.0mmol) to absolute ethanol (180.0mL), heat to reflux to dissolve, filter with suction, continue to reflux the filtrate, and add succinic acid (1.18g, 10.0mmol) in ethanol dropwise to the filtrate The solution (20.0 mL) was incubated for 4 hours, and the above reaction solution was placed in the injection port of a spray dryer, and spray-dried to obtain an off-white solid (3.086 g, 48.6%).

[0144] 2. Identification of the title succinate amorphous

[0145] Through Empyrean X-ray powder diffraction (XRPD) analysis and identification: its X-ray powder diffraction is basically as follows image 3 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to salts of an aminoquinazoline derivative and an application of the salts. The salts of the compound can be a crystalline form, a partially-crystalline form, a heteromorphic form, an amorphous form, a hydrate form or a solvate form. The present invention also relates to a pharmaceutical composition containing the salts or a combination of the salts, and the application of the salts or the pharmaceutical composition in preparation of a medicament for preventing or treating a proliferative disease, atherosclerosis or pulmonary fibrosis.

Description

technical field [0001] The invention belongs to the field of medicines, and relates to salts of aminoquinazoline derivatives and uses thereof, in particular to (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-(methyl Oxy-D 3 )-quinazolin-6-yl)-4-((4aR,7aS)-tetrahydro-2H-[1,4]dioxalo[2,3-c]pyrrol-6(3H)-yl) The salt of but-2-enamide (compound represented by formula (I)) and its use further relate to a pharmaceutical composition comprising said salt. Said salt or said pharmaceutical composition is used for preventing or treating proliferative diseases, atherosclerosis or pulmonary fibrosis. The salts of the compounds of the present invention may be in crystalline, partially crystalline, polymorphic, amorphous, hydrate or solvate form. Background technique [0002] Protein kinases (PKs) represent a large class of proteins that play an important role in the control of cellular functions and the regulation of various cellular lesions, and can be divided into two categories: protein ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D491/056A61K31/517A61P35/00A61P35/04A61P9/10A61P11/00
CPCC07B2200/13C07D491/056
Inventor 陈亮章维红皇甫德胜李成蹊刘兵张英俊聂飚许娟吴族平劳锦花余天喜
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com